MedicarePartD.guide

A non-government resource built from CMS public data

CDK4/6 inhibitors for breast cancer on AARP Medicare Rx Preferred from UHC (S5921-394)

Ibrance, Kisqali and Verzenio, checked against this plan's 2026 formulary (its list of covered drugs).

Plan type
Stand-alone drug plan (PDP), Michigan
Premium
$78.30/month
Deductible
$130.00, doesn't apply to tier 1 and 2
Change plan

3 of 3 CDK4/6 inhibitors are covered on this plan. All 3 require prior authorization.

  • Ibrance
    palbociclib
    Covered · prior auth
    from $5,944.04
    Tier 5
  • Kisqali
    ribociclib
    Covered · prior auth
    from $3,279.98
    Tier 5
  • Verzenio
    abemaciclib
    Covered · prior auth
    from $5,612.51
    Tier 5

Patient cost for a 30-day supply at a preferred retail pharmacy, after the $130.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.

Full plan details · This plan's whole drug list